Ab Interno Canaloplasty (Abic) - Modern Minimally Invasive Glaucoma Surgery In One Year's Observation - Own Experience.
Published 2023 - 41st Congress of the ESCRS
Reference: PO0870 | Type: Free paper | DOI: 10.82333/7s9w-np57
Authors: Wojciech Wiktor Maruszczyk* 1 , Łukasz Drzyzga 1 , Michał Bogocz 2 , Marta Świerczyńska 2 , Katarzyna Gontarz 2 , Michalina Gałuszka 2 , Aleksandra Bukowska 2 , Mariola Dorecka 2 , Dorota Wyględowska-Promieńska 2 , Ewa Mrukwa-Kominek 2
1Department of Ophthalmology,Prof. K. Gibinski University Clinical Center, Medical University of Silesia in Katowice,Katowice,Poland, 2Department of Ophthalmology,Prof. K. Gibinski University Clinical Center, Medical University of Silesia in Katowice,Katowice,Poland;Department of Ophthalmology,Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice,Katowice,Poland
Purpose
Canaloplasty is a surgical glaucoma treatment method that improves the physiological outflow of aqueous humor through the Schlemm's canal. There are many modifications of this method, both with the ab interno and ab externo access. The aim of the study is to evaluate the efficacy and safety of ABiC for the treatment of open angle glaucoma in various patients in one year observation period.
Setting
Department of Ophthalmology, Prof. K. Gibinski University Clinical Centre, Medical University of Silesia in Katowice, Katowice – Poland
Methods
Patients with glaucoma and uncontrolled intraocular pressure despite maximally tolerable antiglaucoma medications were selected to the study. We included 46 adult patients with various open angle glaucoma subtypes. All of them underwent ABiC procedure between 2017 to 2021 and had at least 12-months of follow-up period. Patients were treated with the ab-interno surgical technique using the iTrack canaloplasty microcatheter (Nova Eye Medical). Only patients with 360-degree successful catheterization were included. After the procedure we assessed the post-operative intraocular pressure, best corrected visual acuity, the number of adverse events and complications and the number of antiglaucoma medications.
Results
After the procedure the mean intraocular pressure reduction was observed. The mean IOP was 27,71±9,05mmHg, 17,05±7,37 mmHg, 17,18±2,79 mmHg, 17,57±1,71 mmHg, 16,5±1,69 mmHg and 14,5±5,05 mmHg before, 1 day, 1, 3, 6, 12 months after the surgery, respectively. The mean usage of the anti-glaucoma topical medications was 2,9±1,02, 1,55±1,39, 2,1±0,74, 2,17±0,75, 2,0±1,2 and 2,14±1,07, before, 1 day, 1, 3, 6, 12 months after the surgery, respectively. No decrease in BCVA and no severe complications were observed. Some of the patients after the surgery were qualified for another antiglaucoma surgery due to insufficient intraocular pressure reduction.
Conclusions
Ab-interno canaloplasty appears to be a safe and effective treatment for glaucoma in all stages of the disease, although further studies are required to assess the long-term effect and late postoperative complication rate